NewAmsterdam Pharma Company N.V. (NAMS)

NGM – Real Time Price. Currency in USD

27.96

+0.34 (1.23%)

Market open: Aug 12, 2026, 12:48 PM EDT

27.62

0.00 (0.00%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

09.08.2026

NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day Transcript

05.08.2026

NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears

NewAmsterdam Pharma NASDAQ: NAMS used its annual Investor Day to outline its cardiovascular outcomes strategy for obicetrapib, provide updates on additional clinical programs and discuss commercial preparations ahead of a potential European launch.

05.08.2026

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates

NewAmsterdam Pharma Company N.V. (NAMS) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.48.

05.08.2026

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

– Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe – – PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027 – – Topline data from RUBENS Phase 3 expected by year-end 2026 – – $678.3 million in cash, cash equivalents and marketable securities at June 30, 2026 – – Company to host investor day today at 9:00 AM ET in New York City – NAARDEN, the Netherlands and MIAMI, Aug. 05, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced financial results for the quarter ended June 30, 2026 and provided a corporate update.

Videos

No Data

There is no data to display

Press releases

05.08.2026

NewAmsterdam Pharma Company N.V. (NAMS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

NewAmsterdam Pharma Company N.V. (NAMS)

NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day Transcript

NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

Videos

No Data

Press releases

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day Transcript

NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

Videos

No Data

Press releases

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

Search stocks

NewAmsterdam Pharma Company N.V. (NAMS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

NewAmsterdam Pharma Company N.V. (NAMS)

NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day Transcript

NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

Videos

No Data

Press releases

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day Transcript

NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

Videos

No Data

Press releases

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results